Key result
COVID-19 Omicron infection was associated with a significantly higher risk of myasthenia gravis exacerbation compared to no infection (18.8% vs. 7.3%; HR 3.38, 95% CI 1.20-9.53, p=0.021).
Why the study?
It was unknown whether COVID-19 Omicron infection is associated with exacerbations in patients with myasthenia gravis.
Does COVID-19 Omicron infection increase the risk of exacerbation in Myasthenia Gravis patients?
Cohort (n=289)
Does COVID-19 Omicron infection increase the risk of exacerbation in Myasthenia Gravis patients?
COVID-19 Omicron infection significantly increases the risk of disease exacerbation in patients with Myasthenia Gravis.
Omicron infection associated with MG exacerbations; hypothesis-generating in Level 5 data and needs prospective confirmation.
OBJECTIVE: The aim of this study is to ascertain whether COVID-19 Omicron infection is associated with exacerbations in these myasthenia gravis (MG) patients. RESULT: In total, 289 MG patients (comprising 60% females, with an average age of 46 ± 15 years) were enrolled. A total of 80.9% of MG patients reported a COVID-19 infection, with the majority experiencing a benign course (88%). MG patients who experienced COVID-19 infection demonstrated a higher likelihood of MG exacerbation, compared to those without the infection (18.8% vs. 7.3%, p = 0.039). In the survival analysis, after adjusting for confounding factors, the hazard ratio (HR) for exacerbation post-infection was found to be 3.38 (95% CI 1.20-9.53, p = 0.021). Compared to the exacerbation rates observed in JTA21, an increase was noted in DTM23 among COVID-19-infected MG patients (4.4% vs. 17.2%, p < 0.001). CONCLUSION: The COVID-19 is the risk of MG exacerbation.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2024) conducted a cohort in Myasthenia Gravis (n=289). COVID-19 Omicron infection vs. No COVID-19 infection was evaluated on Myasthenia gravis exacerbation (HR 3.38, 95% CI 1.20-9.53, p=0.021). COVID-19 Omicron infection was associated with a significantly higher risk of myasthenia gravis exacerbation compared to no infection (18.8% vs. 7.3%; HR 3.38, 95% CI 1.20-9.53, p=0.021).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: